Navigation Links
MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
Date:8/18/2008

UNION CITY, Calif. and SHANGHAI, China, Aug. 18 /PRNewswire-FirstCall/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the nomination of MRX- I as its first preclinical development candidate. MRX-I is an antibacterial molecule targeting multi-drug resistant gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Simultaneously, the company expanded its operations in China to increase MicuRx' capacity in antibacterial drug discovery and development.

"Only 12 months after initial funding, we have discovered multiple drug leads and selected our first development candidate MRX-I, a promising antibacterial compound that we expect to be superior to many of the top- selling antibiotics available today," said Zhengyu Yuan, Ph.D., president and chief executive officer of MicuRx Pharmaceuticals, Inc. "This enhanced productivity is owed in part to our hybrid business model that leverages the drug discovery capacity readily available in China and the superior management expertise in the United States."

"MRX-I and additional MicuRx pipeline leads have been identified using our proprietary drug discovery platform," commented Mike F. Gordeev, Ph.D., executive vice president and chief scientific officer of MicuRx. "We will continue to leverage this novel platform to further enhance the pharmacological properties and safety profile of clinically validated antibiotic classes, creating best-in-class antibiotics capable of addressing the growing problem of the bacterial multi-drug resistance."

MicuRx raised $10 million in 2007 with Morningside Group as the sole investor. To facilitate the development of its lead compounds and expand the research capacity, MicuRx recently moved its research and development operations in China to a new 10,000 square-foot facility in ZhangJian HighTech Park in Shanghai, China. The company intends to use this integra
'/>"/>

SOURCE MicuRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
2. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
3. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
4. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
5. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
9. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
10. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2Alberta companies delivering new products to the health & medical marketplace 2
Breaking Biology News(10 mins):New understanding of how to prevent destruction of a tumor suppressor 2Study shows nearly 1/3 of human genome is involved in gingivitis 2Study shows nearly 1/3 of human genome is involved in gingivitis 3Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 1Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 2Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 3Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 4Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 5Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 6Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 7Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain 47450 1Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain 47450 2Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain 47450 3Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 1Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 2Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 3Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 4Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 5